The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Fexofenadine Hydrochloride 120 mg Film-coated tablets



Azure Pharmaceuticals LtdPA22871/004/002

Main Information

Trade NameFexofenadine Hydrochloride 120 mg Film-coated tablets
Active SubstancesFexofenadine hydrochloride
Dosage FormFilm-coated tablet
Licence HolderAzure Pharmaceuticals Ltd
Licence NumberPA22871/004/002

Group Information

ATC CodeR06AX26 fexofenadine

Status

License statusAuthorised
Licence Issued26/06/2020
Legal statusProduct not subject to medical prescription
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to the general public
Conditions of LicenceThe applicant has committed to a maximum pack size restriction of 30 tablets.
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back